Suggested remit: To appraise the clinical and cost effectiveness of depemokimab within its marketing authorisation for treating chronic rhinosinusitis with nasal polyps.
The Department for Health and Social Care has asked NICE to carry out an evaluation of depemokimab for treating chronic rhinosinusitis with nasal polyps ID6449. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that market depemokimab have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience. As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns, please contact the project manager for this scoping exercise, Emily Richards via email on [email protected].
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6449
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 July 2025 - 06 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6449 |
| 01 August 2025 | Suspended. The Department for Health and Social Care has asked NICE to carry out an evaluation of depemokimab for treating chronic rhinosinusitis with nasal polyps ID6449. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that market depemokimab have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience. As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns, please contact the project manager for this scoping exercise, Emily Richards via email on [email protected]. |
| 09 July 2025 | In progress. Scoping commenced |
| 12 December 2024 | Referral |
| 09 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 09 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual